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STATE OF THE SCIENCE  
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The term 'omics' generally refers to fields of studies in biology and 
medicine ending in -omics. The related ending -ome refers to the 
objects of these studies, and implies some sort of totality (e.g. the 
genome is the entirety of the hereditary information in an 
organism). Some of the more popular 'omics' include genomics (except 
for some RNA viruses, this involves studies on DNA), epigenomics 
(studies on chemical changes to DNA and histone proteins), 
transcriptomics (studies on RNA), proteomics (studies on proteins), 
metabolomics (studies on chemical processes involving metabolites), 
pharmacogenomics (studies on the influence of genetic variation on 
drug response), and radiogenomics (studies on the influence of 
genetic variation on radiation-induced normal tissue toxicity). 
Molecular profiling can be used to identify novel targets for 
intervention and for pretherapeutic hypoxic evaluation. There is a 
high degree of heterogeneity in certain tumour sites with respect to 
hypoxia, which can lead to primary resistances to radiotherapy and 
selection of more aggressive tumour phenotypes. The development of 
markers and methods for prediction and proper patient stratification 
is a major research area. Besides molecular profiling, this is often 
addressed using oxygen sensing electrodes or by functional imaging. 
One of the preferred 'omics' for molecular profiling of tumour hypoxia 
is transcriptomics (1). The effect of hypoxia on genome-wide 
transcription levels can be studied in vitro under controlled conditions 
of oxygen tensions, time of exposure, and other environmental 
conditions like extracellular pH. This has led to the development of 
several different gene expression signatures (also known as profiles or 
metagenes). Another approach is to use xenograft models. Finally, 
hypoxia gene expression signatures can be generated by identifying 
candidate genes from in vitro studies and use data from genome-wide 
expression studies on tumour biopsies to analyse and identify 
coexpression networks. In general, and independent on how they have 
been developed, gene expression signatures are associated with poor 
prognosis for the two main cancer types where they have been studied 
most intensely, i.e. head and neck and breast cancer. Recently, one 
of the signatures has also been shown to have predictive value, being 
able to identify patients that benefit from hypoxic modification in a 
randomized trial evaluating the effect of the hypoxic radiosensitizer 
nimorazole (2). Clinical trials on hypoxic radiosensitizers are currently 
being planned, and will hopefully clarify the predictive value of 
hypoxia gene expression signatures. 
Other 'omics' for molecular profiling of tumour hypoxia include 
proteomics and metabolomics. Hypoxia not only affects transcription 
but also translation, and these studies are essential when studying 
signalling pathways and identifying novel targets for intervention, and 
may also provide additional prognostic and predictive value. The 
technologies for genome-wide studies on proteins and metabolites 
have not been as comprehensive and established as for studies on DNA 
and RNA, but with recent technological developments proteomics and 
metabolomics will be increasingly important for molecular profiling of 
tumour hypoxia.  
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In a first part of the talk, state-of-the art methods for non-invasive 
tumour hypoxia imaging using positron emission tomography (PET) will 
be revised. Furthermore, a short overview on currently practised or 
proposed strategies to individualise radiotherapy (RT) based on 
hypoxia PET imaging will be given. 
In a second part, first results of a clinical hypoxia dose painting (HDP) 
carried out in Tübingen trial will be presented. Between 2009 and 
2012, n=21 head and neck cancer (HNC) patients were included into a 
randomized clinical HDP trial. All patients underwent pre-treatment 
[18F]-fluorodesoxyglucose (FDG) PET/CT in addition to dynamic [18F]-
fluoromisonidazole (FMISO) PET/CT imaging. n=16 patients presented 
with a moderate or high level of pre-treatment tumour hypoxia. Those 
were randomized into two different treatment groups: standard IMRT 
(n=8) or HPD consisting of a 10% dose escalation (77 Gy) inside the 
planning target volume of highest order (PTV70) (n=8). Hypoxic 
volumes (HV) were discriminated based on hypoxia and perfusion 
parameters determined by a kinetic analysis of the dynamic FMISO 
PET data. All patients completed pre-treatment imaging examinations 
and RT treatment as planned. Patients randomized into the HDP arm 
did not show increased levels of acute toxicity. After a median follow-
up time of 7 months (0 - 40 months), also no increased levels of late 
toxicities were observed. The mean volume of the PTV was 186.83 ml 
(68.47 - 455.65 ml), whereas the HV had a mean size of 9.37 ml (0 - 
49.17 ml). So far, n=6 local recurrences were observed: 2 in the 
experimental arm and 4 receiving standard IMRT. Technically, the 
integration of dynamic FMISO PET parameters to escalate the dose 
inside the PTV70 was feasible. However, HDP of volumes below a 
critical volume of approximately 2 ml could not be realized due to the 
finite size of dose gradients necessary to increase the dose level by 
10%. 
In a last part of the presentation, the potential of newly available 
hybrid imaging systems combining PET with magnetic resonance 
imaging (PET/MRI) for non-invasive hypoxia imaging will be discussed. 
n=3 patients of the above mentioned study were additionally 
examined with simultaneous PET/MRI including a FMISO PET scan 
approximately 3 h post injection together with a series of diagnostic 
and functional MRI techniques (diffusion weighted, DW and dynamic 
contrast enhanced, DCE). These first clinical FMISO PET/MRI data sets 
hint at a potential correlation of the voxel-based FMISO uptake and 
the local tumour perfusion as measured with DCE-MRI. 
State-of-the-art hypoxia imaging with non-invasive methods is still an 
evolving field of research. Hypoxia imaging using PET/CT and also 
PET/MRI shows a high potential for individualising RT.  
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Tumor hypoxia is a negative prognostic factor in patients treated with 
radiotherapy. This is at least in part because hypoxic cells are 
radiation resistant. Many strategies have consequently been employed 
to overcome the problem of radiation resistant hypoxic cells in the 
clinic. These include the chemical substitution for oxygen with 
hypoxic radiosensitizers or efforts to increase tumor oxygen supply 
with vasodilators and breathing of high-oxygen content gas during 
radiotherapy. Such strategies have proven successful, improving loco-
regional control and survival inpatients with head and neck cancer in 
randomized phase III trials. In spite of this, oxygen modification has 
not entered routine clinical practice in most countries, and we are 
still in need of safe, affordable and practical alternatives to mitigate 
radiation resistance due to tumor hypoxia. A novel class of drugs 
inhibiting mitochondrial activity may represent such an alternative. 
Hypoxia arises distal to blood vessels due to the high oxygen 
consumption of more proximal cells which thereby limit the diffusion 
distance of oxygen in the tumor tissue. Inhibition of oxygen 
consumption by targeting mitochondria can therefore promote 
redistribution of oxygen in tumors and reduce hypoxia. Recent 
promising preclinical data suggest that clinically available inhibitors of 
mitochondrial function are potent tumor radiosensitizers due to their 
ability to reduce the hypoxic fraction.  
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Introduction to the problem: CT was introduced into clinical practice 
in the early 1970s and developing concepts for CT dosimetry attracted 
the interest of many scientists. These efforts finally led to the paper 
by Shope et al. in which the computed tomography dose index (CTDI) 
was introduced. At that time the measurement of CTDI was optimized 
for a narrow CT fan beam geometry, the beam width was usually 
smaller than 10 mm. CTDI measurements are performed with either a 
cylindrical head or body phantom and a 100 mm long pencil ionization 
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chamber.The concept of CTDI is still the basis for dosimetry at modern 
CT scanners, although the assessment of CTDI in phantoms has been 
the subject of much discussion and many revisions were required since 
its initial definition. A fundamental revision was for example needed 
when helical CT was introduced and the concept of pitch had to be 
taken into account. With the introduction of diagnostic wide CT 
beams and the introduction of cone beam computed tomography 
(CBCT) with CT scanners that are integrated with a linear accelerator 
a new problem arose. For these wide CT beams nor the CT dose 
phantoms nor the 100 mm long pencil ionization chamber were 
compatible with the at that time prevailing concept of CTDI. The 
problem was that the beam width of diagnostic wide beam scanners 
and CBCT scanners exceeds the lenght of the cylindrical CT phantoms 
(typically150 mm) and length of the pencil CT ionization chamber (100 
mm) (Geleijns etal.; Wen et al.). 
Solution for diagnostics wide cone beam CT scanners 
As a development to overcome the shortcomings described in the 
previous section, the proposed IEC 60601-2-44 international standard 
(Amendment1 of Edition 3) describes a two tiered approach to the 
definition of CTDI. The first tier is for beam widths ≤ 40 mm and uses 
the conventional definition of CTDI100. In the second tier for beam 
widths > 40mm, it is proposed to measure a reference value for CTDI 
in the standard CT dose phantoms, for anominal beam width of about 
20 mm. This value is then scaled up by the ratio of free in air 
measurements of CTDI for the wide beam condition and the reference 
condition. This approach is also followed in the IAEA Human Health 
Report 5 and is supported by the scientific work from Boone. 
Kilovoltage cone beam CT at the linac’s are a special case since at a 
large field of view the detector is shifted from the centered position, 
this may complicate the measurement of CTDI considerably. 
Assessment of patient dose for cone beam CT scans at the linac’s is 
also complicated. Monte Carlo calculations or measurements with 
anthropomorphic phantoms may be performed. A pragmatic approach 
may be to adhere to the methodology that is often used for diagnostic 
CTscanners, i.e. to use a body part specific conversion factor for 
calculating effective dose from dose-length product. 
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According to the MIRD formalism: 
 
Where  is the absorbed dose in target k from source h, Ãh is 
the cumulated activity in source h, and  is the mean absorbed 
dose per unit cumulated activity from source h to target k (also known 
as "S factor"). This, in theory, divides the calculation of the absorbed 
dose in 2 steps: determination of cumulated activity and computation 
of the S factor. 
When Ãh is obtained from a group of patients, or healthy volunteers, 
or from extrapolation from animal data, and when is obtained 
from a model (anthropomorphic phantom), the resulting absorbed 
dose is therefore suited for model dosimetry, i.e. to provide for 
estimates of the absorbed dose delivered to an hypothetical patient, 
rather than the patient that actually benefited from the nuclear 
medicine procedure. That kind of approach corresponds to the 
situation of radiopharmaceutical administration in a diagnostics 
context, where the injected activity is not supposed to induce 
deterministic effects. The ICRP tables give, for each 
radiopharmaceutical, an estimate of the absorbed dose delivered per 
MBq injected. These should be used in nuclear medicine departments: 
every patient should be given an estimate of the absorbed dose 
delivered during the procedure, even in a diagnostic context. 
In a therapeutic context, the delivered absorbed doses are within the 
range of appearance of deterministic effects. It is therefore important 
to increase the level of accuracy for the determination of the 
absorbed dose. A first step to achieve that goal is to assess the 
radiopharmaceutical uptake for every patient. This requires 
quantitative imaging and pharmacokinetics assessment procedures, 
and thus provides for a specific determination of Ãh.  
However, it is not always possible to derive specific values 
for . A possible means is to adjust model-based S factors in 
order to increase the specificity of the calculation. There are several 
means to achieve this, however one should keep in mind that the end-
result will still be a model-based absorbed dose computation (more or 
less realistic, as a function of the hypothesis adopted for adjusting 
model-based S factors to a given patient). 
Finally, whenever possible, in a therapeutic context, a full patient-
specific dosimetry should be performed. This requires patient-specific 
activity – and cumulated activity – determination, and computation of 
patient-specific S factors. This is the only way to obtain a real 
patient-specific absorbed dose assessment. The availability of CT-
based geometry definition combined with the spread of radiation 
transport modeling codes and the ever-growing computing power 
available now make this option a viable one in a clinical context. 
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Population doses from radiodiagnostic (x-ray and nuclear medicine) 
procedures in Europe were estimated for the first time in the recent 
DOSE DATAMED 2 (DDM2) project (www.ddmed.eu) launched by the 
European Commission. Data of 36 countries was collected to an 
established database.  
The results of the data collection and analysis lead to the following 
conclusions of the overall total collective effective doses in European 
countries:   
For x-ray procedures in EU-countries and EFTA countires (Norway, 
Iceland and Switzerland) the collective effective dose is 544700 
manSv, or 1,065 manSv per 1000 of population, resulting in a mean 
effective dose of 1,07 mSv per caput.  For all European countries 
included in the DDM2 survey the collective effective dose was 605010 
manSv, or 1,052 manSv per 1000 of population, resulting in a mean 
effective dose of 1,05 mSv per caput.    
For NM procedures in EU-countries and EFTA countries the collective 
effective dose is 30781 manSv, or 60,2 manSv per milion of 
population, resulting in a mean effective dose of 0,060 mSv per 
caput.  For all European countries included in the DDM2 survey the 
collective effective dose is 31336 manSv, or 54,5 manSv per million of 
